Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY17.31
+0.44 (+2.61%)
CN SHZ Healthcare Medical - Diagnostics & Research
Address
No.8 Lizhishan Road
Guangzhou, CN
Guangzhou, CN
CEO
Zhongxiong Peng
Website
wondfo.com.cn
IPO
2015-06-30
ISIN CNE100002102
Description
Guangzhou Wondfo Biotech Co.,Ltd operates as a biotechnology enterprise, specializing in the research, development, production, and distribution of point-of-care testing (POCT) products. The company additionally provides rapid diagnostic tools and comprehensive solutions for managing chronic diseases. Its product catalog features an array of rapid test kits, addressing conditions like COVID-19, substance abuse, certain cancers, infectious diseases, fertility, and sexually transmitted infections. Furthermore, Wondfo Biotech offers immunofluorescence devices designed to identify cardiovascular conditions, inflammatory markers, kidney damage, hormonal imbalances (including sex hormones and thyroid function), diabetes, and specific tumor indicators. The firm also supplies analytical instruments, such as blood gas, optical coagulation, and dry chemistry analyzers. Established in 1992, the company's main operations are based in Guangzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.31
+0.44 (+2.61%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.87
Float Shares
254.13M
Free Float %
54.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.62% | -1.82% | -2.84% | -12.46% | -16.02% | -10.03% | -16.46% | -40.67% | -75.30% | -5.13% | +261.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.31
DCF (Unlevered)
5.75
-66.8%
DCF (Levered)
5.08
-70.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.59
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-31.9% Q1'26: -27.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-110.7% Q1'26: -53.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+4.2% Q1'26: +34.5% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-4.0% Q1'26: +18.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-2.2% Q1'26: +8.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+4.5% Q1'26: -3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.05× ★ Q1'26: 1.60× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
428.78M
est: 432.00M (-0.7%)
|
547.35M
est: 550.00M (-0.5%)
|
1.15B
est: 1.04B (+10.1%)
|
1.65B
est: 1.64B (+0.5%)
|
2.07B
est: 2.07B (+0.1%)
|
2.81B
est: 3.01B (-6.5%)
|
3.36B
est: 3.23B (+4.1%)
|
5.68B
est: 5.68B (0.0%)
|
2.76B
est: 2.85B (-3.0%)
|
3.06B
est: 3.19B (-4.0%)
|
2.09B
est: 2.30B (-9.3%)
|
2.57B
2.49B – 2.67B
+11.5% YoY
|
2.92B
2.85B – 3.06B
+14.0% YoY
|
3.33B
3.32B – 3.35B
+13.9% YoY
|
| EBITDA |
132.45M
est: 119.16M (+11.2%)
|
164.52M
est: 151.71M (+8.4%)
|
295.76M
est: 286.90M (+3.1%)
|
459.76M
est: 452.93M (+1.5%)
|
621.01M
est: 571.19M (+8.7%)
|
965.33M
est: 829.02M (+16.4%)
|
817.30M
est: 890.96M (-8.3%)
|
1.57B
est: 1.57B (+0.1%)
|
709.10M
est: 639.87M (+10.8%)
|
796.73M
est: 716.27M (+11.2%)
|
179.91M
est: 516.33M (-65.2%)
|
575.89M
559.46M – 598.30M
+11.5% YoY
|
656.30M
639.12M – 686.10M
+14.0% YoY
|
747.58M
744.17M – 751.00M
+13.9% YoY
|
| EBIT |
111.26M
est: 92.74M (+20.0%)
|
136.89M
est: 118.07M (+15.9%)
|
247.14M
est: 223.29M (+10.7%)
|
387.82M
est: 352.50M (+10.0%)
|
515.05M
est: 444.55M (+15.9%)
|
825.49M
est: 645.21M (+27.9%)
|
634.64M
est: 693.41M (-8.5%)
|
1.32B
est: 1.22B (+8.6%)
|
456.73M
est: 421.84M (+8.3%)
|
590.27M
est: 472.21M (+25.0%)
|
-83.55M
est: 340.40M (-124.5%)
|
379.66M
368.83M – 394.44M
+11.5% YoY
|
432.67M
421.35M – 452.32M
+14.0% YoY
|
492.85M
490.60M – 495.10M
+13.9% YoY
|
| Net Income |
125.35M
est: 131.11M (-4.4%)
|
144.99M
est: 178.52M (-18.8%)
|
210.70M
est: 236.05M (-10.7%)
|
307.74M
est: 321.34M (-4.2%)
|
387.46M
est: 400.60M (-3.3%)
|
634.17M
est: 670.03M (-5.4%)
|
634.43M
est: 867.97M (-26.9%)
|
1.20B
est: 1.25B (-4.5%)
|
487.62M
est: 552.06M (-11.7%)
|
561.63M
est: 646.22M (-13.1%)
|
-63.02M
est: 656.01M (-109.6%)
|
421.54M
404.48M – 442.45M
-35.7% YoY
|
492.16M
473.85M – 518.33M
+16.8% YoY
|
585.23M
447.69M – 706.15M
+18.9% YoY
|
| SGA |
170.17M
est: 119.15M (+42.8%)
|
236.10M
est: 151.70M (+55.6%)
|
347.35M
est: 286.88M (+21.1%)
|
501.75M
est: 452.90M (+10.8%)
|
655.21M
est: 571.16M (+14.7%)
|
819.99M
est: 828.97M (-1.1%)
|
910.24M
est: 890.90M (+2.2%)
|
1.16B
est: 1.57B (-26.1%)
|
877.11M
est: 736.55M (+19.1%)
|
905.85M
est: 824.49M (+9.9%)
|
425.97M
est: 594.35M (-28.3%)
|
662.90M
643.99M – 688.70M
+11.5% YoY
|
755.47M
735.69M – 789.77M
+14.0% YoY
|
860.55M
856.62M – 864.48M
+13.9% YoY
|
| EPS |
0.35
est: 0.28 (+23.9%)
|
0.35
est: 0.38 (-9.0%)
|
0.52
est: 0.51 (+2.3%)
|
0.71
est: 0.69 (+2.6%)
|
0.88
est: 0.86 (+2.0%)
|
1.44
est: 1.44 (-0.2%)
|
1.43
est: 1.87 (-23.5%)
|
2.71
est: 2.70 (+0.4%)
|
1.10
est: 1.13 (-2.5%)
|
1.21
est: 1.32 (-8.3%)
|
-0.13
est: 1.34 (-109.7%)
|
0.87
0.83 – 0.91
-35.4% YoY
|
1.01
0.98 – 1.07
+17.1% YoY
|
1.19
0.92 – 1.46
+17.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
186.53M
OE per share TTM
0.40
Owner's Yield
2.25%
Maintenance CapEx ratio
132.79%
Maint CapEx / Avg PPE
34.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 25 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 81.6K | 0.65% |
| 2 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 76.0K | 0.19% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 63.2K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 222.2K | 0.39% |
| 5 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 118.9K | 0.06% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 80.8K | 0.29% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.6K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 24.0K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.18M | 0.06% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 63.4K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-26.1K
Shares Outstanding
468.09M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cai Mei Peng | Accounting Supervisor | — | — |
| Fang Xia Yu | Chief Financial Officer & Deputy GM | — | female |
| Hong Hu | Board Secretary | — | female |
| Ke Ren Kang | Deputy General Manager | — | female |
| Yaping Zhao | Deputy General Manager & Non-Independent Director | — | male |
| Zhongxiong Peng | GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300482.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
